Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL. The dose and schedule of JCAR017 will be evaluated and modified, as needed, for safety and antitumor activity. We will also determine how long the modified T cells stay in the patient's body and how well JCAR017 works in treating patients with non-Hodgkin's lymphoma whose disease has come back or has not responded to treatment.
A Phase I, Multicenter, Open-Label Study of JCAR017, CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)
- ClinicalTrials.gov Identifier: NCT02631044
- Protocol Number: 15-404
- Principal Investigator: Jon Arnason
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required